Limits...
RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma.

Tezval H, Merseburger AS, Matuschek I, Machtens S, Kuczyk MA, Serth J - BMC Urol (2008)

Bottom Line: Survival analysis was carried out for 187 patients considering a follow-up period of 2-240 month.Expression of RASSF1A was found to be significantly decreased in tumoral cells when compared to normal tubular epithelial cells.Thus RCC tumorigenesis without depletion of RASSF1A may be associated with an adverse clinical outcome.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Urology, Medizinische Hochschule Hannover, Hannover, Germany. tezval.hossein@mh-hannover.de

ABSTRACT

Background: Epigenetic silencing of RAS association family 1A (RASSF1A) tumor suppressor gene occurs in various histological subtypes of renal cell carcinoma (RCC) but RASSF1A protein expression in clear cell RCC as well as a possible correlation with clinicopathological parameters of patients has not been analyzed at yet.

Methods: 318 primary clear cell carcinomas were analyzed using tissue microarray analysis and immunohistochemistry. Survival analysis was carried out for 187 patients considering a follow-up period of 2-240 month.

Results: Expression of RASSF1A was found to be significantly decreased in tumoral cells when compared to normal tubular epithelial cells. RASSF1A immunopositivity was significantly associated with pT stage, group stage and histological grade of tumors and showed a tendency for impaired survival in Kaplan-Meier analysis.

Conclusion: While most tumors demonstrate a loss of RASSF1A protein, a subset of tumors was identified to exhibit substantial RASSF1A protein expression and show increased tumor progression. Thus RCC tumorigenesis without depletion of RASSF1A may be associated with an adverse clinical outcome.

Show MeSH

Related in: MedlinePlus

Differential expression of RASSF1A in clear cell carcinoma of the kidney. Immunohistochemical analysis of RASSF1A expression in CC-RCC specimens exhibiting < 25% (A) and > 25% (B) labeling index.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2572051&req=5

Figure 1: Differential expression of RASSF1A in clear cell carcinoma of the kidney. Immunohistochemical analysis of RASSF1A expression in CC-RCC specimens exhibiting < 25% (A) and > 25% (B) labeling index.

Mentions: The presence of RASSF1A protein in primary tumor specimens and corresponding histologically normal surrounding parenchyma was investigated using immunohistochemical analysis of TMA slides of 318 patients with CC-RCC. Specific immunopositivity for RASSF1A was exclusively observed in the cytoplasm of tumor and normal tubular epithelial cells [7]. Positivity of RASSF1A was found to be significantly decreased in tumoral cells when compared to normal tubular epithelial cells (p < 0.001, paired t-test). In tumors a mean positivity of 19% (median 11%) was detected and 85% of tumors exhibited a RASSF1A labeling index of ≤ 25% (fig. 1 and 2).


RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma.

Tezval H, Merseburger AS, Matuschek I, Machtens S, Kuczyk MA, Serth J - BMC Urol (2008)

Differential expression of RASSF1A in clear cell carcinoma of the kidney. Immunohistochemical analysis of RASSF1A expression in CC-RCC specimens exhibiting < 25% (A) and > 25% (B) labeling index.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2572051&req=5

Figure 1: Differential expression of RASSF1A in clear cell carcinoma of the kidney. Immunohistochemical analysis of RASSF1A expression in CC-RCC specimens exhibiting < 25% (A) and > 25% (B) labeling index.
Mentions: The presence of RASSF1A protein in primary tumor specimens and corresponding histologically normal surrounding parenchyma was investigated using immunohistochemical analysis of TMA slides of 318 patients with CC-RCC. Specific immunopositivity for RASSF1A was exclusively observed in the cytoplasm of tumor and normal tubular epithelial cells [7]. Positivity of RASSF1A was found to be significantly decreased in tumoral cells when compared to normal tubular epithelial cells (p < 0.001, paired t-test). In tumors a mean positivity of 19% (median 11%) was detected and 85% of tumors exhibited a RASSF1A labeling index of ≤ 25% (fig. 1 and 2).

Bottom Line: Survival analysis was carried out for 187 patients considering a follow-up period of 2-240 month.Expression of RASSF1A was found to be significantly decreased in tumoral cells when compared to normal tubular epithelial cells.Thus RCC tumorigenesis without depletion of RASSF1A may be associated with an adverse clinical outcome.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Urology, Medizinische Hochschule Hannover, Hannover, Germany. tezval.hossein@mh-hannover.de

ABSTRACT

Background: Epigenetic silencing of RAS association family 1A (RASSF1A) tumor suppressor gene occurs in various histological subtypes of renal cell carcinoma (RCC) but RASSF1A protein expression in clear cell RCC as well as a possible correlation with clinicopathological parameters of patients has not been analyzed at yet.

Methods: 318 primary clear cell carcinomas were analyzed using tissue microarray analysis and immunohistochemistry. Survival analysis was carried out for 187 patients considering a follow-up period of 2-240 month.

Results: Expression of RASSF1A was found to be significantly decreased in tumoral cells when compared to normal tubular epithelial cells. RASSF1A immunopositivity was significantly associated with pT stage, group stage and histological grade of tumors and showed a tendency for impaired survival in Kaplan-Meier analysis.

Conclusion: While most tumors demonstrate a loss of RASSF1A protein, a subset of tumors was identified to exhibit substantial RASSF1A protein expression and show increased tumor progression. Thus RCC tumorigenesis without depletion of RASSF1A may be associated with an adverse clinical outcome.

Show MeSH
Related in: MedlinePlus